Of these, however, only the SLC2A6 glucose transporter displayed a clear decrease in steady-state protein levels after CR-31 treatment in KP organoids (Fig. 5b, Supplementary Fig. 11a) and patient-derived PDA cell lines (Fig. 5c). Here, SLC2A6 is linked to Patent ductus arteriosus.